New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia
del Campo, M. (Departamento de Ciencias Farmacéuticas y de la Salud. Facultad de Farmacia. Universidad San Pablo-CEU. CEU Universities)
Zetterberg, Henrik (Hong Kong Center for Neurodegenerative Diseases)
Gandy, S. (Department of Neurology. Icahn School of Medicine at Mount Sinai)
Onyike, C.U. (Division of Geriatric Psychiatry and Neuropsychiatry. The Johns Hopkins University School of Medicine)
Oliveira, F. (Department of Neurology and Neurosurgery. Escola Paulista de Medicina. Federal University of São Paulo (UNIFESP))
Udeh-Momoh, C. (Translational Health Sciences. Faculty of Medicine. University of Bristol)
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau)
Teunissen, C.E. (Neurochemistry Laboratory. Department of Clinical Chemistry. Amsterdam Neuroscience. Amsterdam University Medical Centers. Vrije Universiteit)
Pijnenburg, Y. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam. Amsterdam UMC)

Fecha:	2022
Resumen:	Frontotemporal dementia (FTD) covers a spectrum of neurodegenerative disorders with different phenotypes, genetic backgrounds, and pathological states. Its clinicopathological diversity challenges the diagnostic process and the execution of clinical trials, calling for specific diagnostic biomarkers of pathologic FTD types. There is also a need for biomarkers that facilitate disease staging, quantification of severity, monitoring in clinics and observational studies, and for evaluation of target engagement and treatment response in clinical trials. This review discusses current FTD biofluid-based biomarker knowledge taking into account the differing applications. The limitations, knowledge gaps, and challenges for the development and implementation of such markers are also examined. Strategies to overcome these hurdles are proposed, including the technologies available, patient cohorts, and collaborative research initiatives. Access to robust and reliable biomarkers that define the exact underlying pathophysiological FTD process will meet the needs for specific diagnosis, disease quantitation, clinical monitoring, and treatment development.
Ayudas:	European Research Council 681712 European Commission. Horizon 2020 860197
Nota:	Altres ajuts: The Swedish Research Council (#2018-02532); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF) (#201809-2016862); the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the UK Dementia Research Institute at UCL; The Robert and Nancy Hall Brain Research Fund.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article de revisió ; recerca ; Versió publicada
Materia:	Biomarkers ; Frontotemporal Dementia ; Humans ; Neurodegenerative Diseases
Publicado en:	Alzheimer's & Dementia, Vol. 18 Núm. 11 (november 2022) , p. 2292-2307, ISSN 1552-5279

DOI: 10.1002/alz.12643
PMID: 35235699

16 p, 567.6 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados